Global Resistance of Neisseria gonorrhoeae

When Theory Becomes Reality

David A. Lewis


Curr Opin Infect Dis. 2014;27(1):62-67. 

In This Article


The lack of quality regional surveillance AMR data means it is presently impossible to estimate the global burden of MDR and XDR gonorrhoea. However, it is clear that control of gonorrhoea is failing at the global level, and we are seeing both increases in the incidence of new gonorrhoea cases and a worsening of the AMR profile of N. gonorrhoeae. Current strategies to control gonococcal AMR should include, where possible, the use of higher doses of ceftriaxone given as dual therapy with an effective second antimicrobial agent and continued evaluation of alternative drug combinations for both urogenital as well as rectal and oropharyngeal gonorrhoea. The recent emergence of the XDR gonococcal 'superbug' strongly argues the case for investment in research and development for both novel antimicrobial agents and, most importantly of all, a gonococcal vaccine.